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AbstrAct:
Inactivation of tumor suppressor gene p16/INK4A and oncogenic activation of 
KRAS occur in almost all pancreatic cancers. To better understand the roles of 
p16 in pancreatic tumorigenesis, we created a conditional p16 knockout mouse 
line (p16flox/flox), in which p16 is specifically disrupted in a tissue-specific manner 
without affecting p19/ARF expression. p16flox/flox;  LSL-KrasG12D;  Pdx1-Cre mice 
developed the full spectrum of pancreatic intraepithelial neoplasia (mPanIN) 
lesions, pancreatic ductal adenocarcinoma (PDA), and metastases were observed 
in all the mice. Here we report a mouse model that simulates human pancreatic 
tumorigenesis at both genetic and histologic levels and is ideal for studies of 
metastasis. During the progression from primary tumors to metastases, the wild-
type allele of Kras was progressively lost (loss of heterozygosity at Kras or LOH 
at Kras) in p16flox/flox; LSL- KrasG12D; Pdx1-Cre mice. These observations suggest a 
role for Kras beyond tumor initiation. In vitro assays performed with cancer cell 
lines derived from primary pancreatic tumors of these mice showed that cancer cells 
with LOH at Kras exhibited more aggressive phenotypes than those retained the 
wild-type Kras allele, indicating that LOH at Kras can provide cancer cells functional 
growth advantages and promote metastasis. Increased LOH at KRAS was also 
observed in progression of human pancreatic primary tumors to metastases, again 
supporting a role for the KRAS gene in cancer metastasis. This finding has potential 
translational implications- future KRAS target therapies may need to consider 
targeting oncogenic KRAS specifically without inhibiting wild-type KRAS function.
 INtrODUctION
Pancreatic cancer is the 5th leading cause of cancer 
deaths in the United States. The 5-year survival rate is only 
5%, despite significant increases in our understanding of 
the molecular events that mediate its onset and progression 
[1]. More reliable early detection methods are needed, as 
well as increased understanding of the mechanisms of 
metastasis and therapeutic resistance [2]. 
KRAS is one of the most frequently activated 
oncogenes in human tumors, with 95% mutation Oncotarget 2011; 2:  862 - 873 863 www.impactjournals.com/oncotarget
frequency in pancreatic carcinomas [3, 4]. Point 
mutations in codon 12 of KRAS (KRASG12D or KRASG12V) 
are the most commonly identified in human pancreatic 
adenocarcinoma. This and other mutations that activate 
KRAS have been found in the earliest stages of pancreatic 
intraepithelial neoplasia (PanIN)-a precursor to infiltrating 
pancreatic ductal adenocarcinoma (PDA). PanIN can be 
divided into different grades (1A, 1B, 2 and 3) according 
to the degree of architectural and cytological atypia [5]. 
This association between KRAS mutations and PanIN, 
along with data from in vitro transformation assays, 
support the concept that pancreatic tumorigenesis can be 
initiated by activated KRAS. 
Cellular responses to Ras activation vary and 
depend on the cell type, Ras isoform, expression level, 
and wild-type allele status [6, 7]. For example, targeted 
overexpression of activated Kras in the pancreas often 
leads to the development of pancreatic acinar hyperplasia 
or dysplasia, but not invasive cancer [8, 9]. Conversely, 
expression of activated KrasG12D at a physiological level 
(in LSL-KrasG12D mice), induced by Pdx1-Cre or p48-Cre, 
is sufficient to initiate the development of murine PanIN, 
some of which progress to PDA after a period of latency 
[10, 11]. The oncogenic function of mutant Kras protein is 
therefore significantly influenced by the expression level 
of the mutant Kras allele or the ratio of the wild-type to 
mutant Kras protein. Increasing evidence supports the 
latter hypothesis that the wild-type Kras allele can also 
impact cellular responses [7, 12, 13]. 
A human PDA sample contains an average of 63 
genetic alterations [14]. Among them, p16  (INK4A) 
is inactivation in virtually all human PDA [15]. The 
Figure 1
Figure 1: Tissue-specific inactivation of p16 in mice. (A) Schematic of the PCR strategies for genotyping and detecting Cre-
mediated recombination. (B) The wild-type (p16+/+), p16flox/+, and p16flox/flox genotypes were identified by PCR. (C) The recombined fragment 
of p16 was detected only in mice with Cre transgene expression, and in the pancreas and intestine, but not in the other tissues of adult p16flox/
flox; Pdx1-Cre mice (D). (E) Histological and immunohistochemical analyses of pancreatic sections from p16flox/flox; Pdx1-Cre mice showed 
normal development of pancreatic cell lineages with significant reduction of p16 protein expression. Oncotarget 2011; 2:  862 - 873 864 www.impactjournals.com/oncotarget
molecular mechanisms of p16 inactivation include 
promoter methylation, missense mutation, and small 
deletion accompanied by loss of heterozygosity (LOH) 
[15, 16]. Other than small deletions, methylation and 
missense mutations specifically targeted p16 and did not 
involve p14 (ARF), another tumor-suppressor gene with 
distinctive protein structure and function but shares coding 
exons with p16 [15-20]. In mice, activation of Kras alone 
is  sufficient  to  induce  the  development  of  preinvasive 
lesions [11], and the deletion of the p16/19 (INK4A/ARF) 
locus rapidly advances progression to invasive cancer as 
observed in LSL- KrasG12D; p16/19-/-; Pdx1-Cre mice [18, 
21]. However, the role of p16 in pancreatic tumorigenesis 
cannot be separated from that of p19 in this model [18, 
21].  p16-/- mice (which retain p19/ARF) spontaneously 
develop and die from a variety of malignant tumors, 
including soft-tissue sarcoma, lymphoma, and melanoma 
[22], so the potential tumorigenic effects of p16 loss in 
the pancreas are not known. To investigate the role of p16 
in pancreatic tumorigenesis, the most frequently mutated 
gene in human PDA, we generated conditional p16 
knockout mice. In these mice only exon1α of the p16/19 
locus is flanked by loxP sites, to inactivate only the p16 
allele  in  a  tissue-specific  manner  without  affecting  the 
expression of p19. 
rEsULts
Targeted deletion of p16 in the pancreas does not 
affect development of pancreatic cell lineages
In  p16flox/flox  mice,  exon1α  of  both  alleles  of  p16 
alleles are flanked by loxP sites (Fig. 1). Mutant p16flox/flox; 
Pdx1-Cre mice were born at normal frequency and had no 
evidence of gross anatomic or physiological abnormalities. 
In adult p16flox/flox; Pdx1-Cre mice, tissue-specific genomic 
recombination of p16 was restricted to the pancreas and 
intestine (Fig. 1D). The expression levels of amylase, 
insulin, and glucagon in the mutant mice appeared normal 
(Fig. 1E and data not shown). Immunohistochemical 
analysis demonstrated the loss of the p16 nuclear labeling 
in all three pancreatic cell lineages in the p16 flox/flox; Pdx1-
Figure 2: Effects of p16 inactivation and Kras activation on survival and pancreatic tumor development. (A) The 
median survival time was 15.5± 3.8 weeks (n=36) for p16-/-; LSL-KrasG12D; Pdx1-Cre mice and   25.5± 8.9 weeks (n=16) for p16flox/flox; 
LSL-KrasG12D; Pdx1-Cre mice. The control mice were mixed genotypes without the LSL- KrasG12D allele; n=115. (B) The most common 
histologic variant in the p16-/-; LSL-KrasG12D; Pdx1-Cre and p16flox/flox; LSL-KrasG12D; Pdx1-Cre mouse models was comprised predominantly 
of malignant glands characterizing as well to moderately differentiated adenocarcinoma (a) with a minor component composed of more 
poorly differentiated components of sarcomatoid (b) and undifferentiated anaplastic (c) carcinoma. Shown here are representative histology 
from p16-/-; LSL-KrasG12D; Pdx1-Cre mice. 
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Cre mice, while diffuse nuclear labeling for p16 was 
observed in the pancreas of the p16 flox/flox control mice (Fig. 
1E). The mutant and control mice had similar responses to 
the glucose tolerance test (data not shown). Finally, none 
of the p16flox/flox; Pdx1-Cre mice under 18 months of age 
(n=16) developed pancreatic neoplasms, therefore p16 
inactivation alone is not sufficient to initiate pancreatic 
tumorigenesis.
Combined p16  inactivation  and  Kras activation 
promote  pancreatic  tumor  progression  and 
metastasis
To explore the dynamics of combined p16 biallelic 
inactivation and Kras activation in pancreatic tumor 
development and progression in the setting of intact 
p19,  p16-/-;  LSL- KrasG12D;  Pdx1-Cre mice and p16flox/
flox;  LSL- KrasG12D;  Pdx1-Cre mice were generated and 
characterized. p16-/-; LSL- KrasG12D; Pdx1-Cre mice and 
p16flox/flox; LSL- KrasG12D; Pdx1-Cre mice had dramatically 
reduced median survival time (15.5± 3.8 weeks, n=36, 
and 25.5± 8.9 weeks, n=16, respectively) compared with 
p16+/+; LSL- KrasG12D; Pdx1-Cre mice (~15 months) [11] 
(Fig. 2A).
Other than the differences in median survival, 
the p16-/-; LSL- KrasG12D; Pdx1-Cre and p16flox/flox; LSL- 
KrasG12D; Pdx1-Cre mice were very similar in their tumor 
development and metastasis patterns. Mice of the p16-/-; 
LSL- KrasG12D; Pdx1-Cre genotype were normal until 6 
weeks of age. Between 6 and 24 weeks of age, they started 
to exhibit weight loss, jaundice, ascites, and increased 
abdominal girth (Fig. S2). A series of autopsies revealed 
the presence of solid pancreatic tumors ranging from 3 
to 30 mm in diameter. The tumors were grossly firm with 
irregular and ill-defined margins, frequently adherent to 
Figure 3: Immunohistochemical features of PDA in p16flox/flox; LSL-KrasG12D; Pdx1-Cre mice. (A) CK19 immunolabeling was 
strong and diffuse in well-differentiated tumor, but negligible in the poorly differentiated or undifferentiated components; (B) Myofibroblasts, 
identified by α-SMA immunostaining, were associated with a desmoplastic stromal response and were commonly associated with invasive 
pancreatic cancer; (C) PDA cells showed increased proliferation, compared with normal tissue, based on increased nuclear staining of Ki-
67; Nuclear expressions of p53 (D) and p19 (E) were detected in PDA. Cyclin D1 (F), Her-2 (G), and Cox-2 (H), and Fascin (I) were also 
overexpressed in PDA. Oncotarget 2011; 2:  862 - 873 866 www.impactjournals.com/oncotarget
adjacent organs (Fig. S2). Multiple tumor nodules were 
often visible, indicating that neoplasms of this genotype 
were multifocal. Histological analysis revealed a glandular 
pattern of well-differentiated to moderately differentiated 
pancreatic adenocarcinomas resembling human PDA 
was the predominant histologic component observed in 
both  mouse  models.  Adenocarcinomas  were  identified 
in 21of 22 invasive carcinomas in p16-/-; LSL- KrasG12D; 
Pdx1-Cre mice and comprised ≥ 50% in 13 of the 21 
invasive carcinomas (Fig. 2B-a, Table S1) and in 9 of 9 
in p16flox/flox; LSL- KrasG12D; Pdx1-Cre mice and comprised 
≥ 50% in 5 of the 9 in p16flox/flox; LSL- KrasG12D; Pdx1-Cre 
mice (Fig. S3f, Table S2). Undifferentiated spindle cell 
and undifferentiated anaplastic components were also 
observed in most carcinomas although at low percentages 
(Fig. 2B, S3, Tables S1, S2). The varied morphologic 
spectrum of tumor phenotypes and heterogeneity within 
individual tumors is a common feature of these models and 
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Figure 4: mPanIN progression in the pancreata of p16-/-; LSL-KrasG12D; Pdx1-Cre mice. (A) An mPanIN lesion might narrow 
or obstruct the interlobular pancreatic duct (arrow); (B) mPanIN-1A with mild atypia (gastric foveolar type epithelium); (C) low-grade 
mPanIN-1B to mPanIN-2 lesion with mild cytologic atypia with focal micropapillary architecture; (D) focal mPanIN-2 lesion associated 
with background PanIN-1 lesion and (E) mPanIN-2 lesion with moderate cytologic atypia with focal micropapillary architecture; (F) 
High-grade mPanIN-3 lesion displays complete loss of cellular polarity, significant nuclear atypia, and budding of cell clusters into the 
ductal lumen. In addition to invasive tumors, pre-invasive occasional intraductal lesions with focal papillary (G, H) and cystic dilation 
(I), and multifocal mPanIN lesions with varying degrees of dysplasia were identified. (J) Histologic assessment of mPanIN progression in 
p16-/-; LSL- KrasG12D; Pdx1-Cre mice. To quantify mPanIN progression, the total number of ducts, including normal and various stages of 
mPanINs, was scored in 3 age groups of p16-/-; LSL- KrasG12D; Pdx1-Cre mice. Percentages (±SEM) of normal (NL) and neoplastic ducts 
by grade (mPanIN-1A, mPanIN-1B, mPanIN-2, and mPanIN-3) in the three groups are presented here. The average age for each group is 
cohort 1, 1.1 months (n=8); cohort 2, 2.9 months (n=5); and cohort 3, 4 months (n=5). Oncotarget 2011; 2:  862 - 873 867 www.impactjournals.com/oncotarget
might result from the multifocal nature of the carcinomas. 
Invasive pancreatic adenocarcinomas expressed 
high levels of CK19 in well-differentiated regions and 
lower levels in sarcomatoid regions (Fig. 3A), whereas 
anaplastic regions showed no reactivity with anti-CK19. 
These anaplastic undifferentiated tumors had high mitotic 
activity, marked nuclear atypia, and dramatic cellular 
pleomorphism. The invasive carcinomas were usually 
associated with a desmoplastic stromal response, as shown 
by positive α-SMA labeling of myofibroblasts (Fig. 3B). 
Ki67 immunoreactivity, which indicates cell proliferation, 
was  significantly  increased  in  PDA  compared  with 
normal pancreatic tissue (Fig. 3C). Increased p53 and 
p19 expressions were most frequently detected at the 
tumor margin, transit areas, and in well-differentiated 
PDA (Fig. 3D, E). Cyclin D1 and Fascin were also highly 
expressed by PDA (Fig. 3F, I). Immunoreactivity for 
Her2 and Cox-2 varied; they were restricted to a subset 
of PDA and undifferentiated sarcomatoid carcinoma (Fig. 
3G, H). Immmunohistochemistry analyses were also 
performed on precancerous lesions. Increasing levels of 
immunoreactivity to Fascin, Ki67, Her-2, Cyclin D1, Cox-
2 were associated with mPanIN progression to invasive 
cancer as they are in humans (Table 1) [23], which further 
validated the similarities between the invasive pancreatic 
tumors found in our models and human PDA. 
The invasive carcinomas that developed in p16-
/-;  LSL- KrasG12D;  Pdx1-Cre mice involved extensive 
amounts of peripancreatic tissue and frequently formed 
metastases. Numbers of metastases increased with age but 
were not restricted to older mice. Table S1 is a summary 
of p16-/-; LSL- KrasG12D; Pdx1-Cre mutant mice that had 
been sacrificed by age for histology analyses. Metastases 
were identified in 44% of the mutant mice (7/16, Table 
S1) that were <4 months-old, 69% of those >4 months 
(9/13). When mutant mice were sacrificed because they 
had reached the non-thriving stage, 100% had metastases 
(n=14). Almost all of the non-thriving animals had overly 
distended abdomens, resulting from the accumulation of 
hemorrhagic ascites (Fig. S2). The distribution pattern of 
the metastases is similar to that of human disease. Most 
metastases involved the liver and regional lymph nodes 
(Fig. S4, Table S1), with direct local invasion of the 
duodenum, stomach, diaphragm, and spleen. Metastases 
to lymph nodes, liver, lung, and testis were also observed 
(Fig. S4). The mice frequently had obstructions of the 
bile duct or small bowel (Fig. S2). The liver metastases 
most frequently had a glandular morphology, with less 
frequent undifferentiated sarcomatoid and anaplastic 
components (Fig. S4). Therefore, not only the invasive 
pancreatic tumors observed in our models mimic human 
PDA, here we also report that the combined p16 biallelic 
inactivation and Kras activation can promote frequent and 
consistent metastases that mimic the distribution pattern 
of metastases observed in advanced human PDA. 
Inactivation  of  p16  did  not  alter  the  histologic 
presentation  of  mPanIN  initiated  by  oncogenic 
Kras
Tumors from p16-/-; LSL- KrasG12D; Pdx1-Cre mice 
were collected from mice at 4–6, 11–13 and 15–17 weeks 
and histologic analyses were performed. A full spectrum 
of mPanIN lesions were observed in the p16-/-; LSL- 
KrasG12D; Pdx1-Cre mice (Fig. 4 B–F), indicating that 
the biallelic inactivation of p16 accelerated but did not 
alter the pathological progression of the LSL- KrasG12D; 
Pdx1-Cre  mice  [11].  At  ~1  month  of  age,  5/8  p16-/-; 
LSL- KrasG12D; Pdx1-Cre mice had focal mPanIN lesions 
(predominantly low grade) but no PDA. The remaining 3 
had normal pancreatic histology (Fig. 4J). At 3-4 months, 
p16-/-; LSL- KrasG12D; Pdx1-Cre mice had a significantly 
increased overall number and advanced grade of mPanINs 
compared with 1-month old mice (Fig. 4J). Mutant mice 
that were >3 months old all had multifocal PDA. High-
grade mPanIN-3 lesions were frequently associated with 
PDA. The control littermates had normal pancreatic 
histology at each time point. Infrequently, focal and 
noninvasive cystic papillary neoplasms, resembling 
human intraductal papillary mucinous neoplasms were 
also observed (Fig. 4G–I) [24]. 
Similar histological progression pattern from 
precancerous lesions to invasive cancer and metastasis was 
also observed in the p16flox/flox; LSL- KrasG12D; Pdx1-Cre 
mice (Fig. S3), again demonstrating that p16 inactivation 
promotes progression but does not alter tumor initiation 
Table  1:  Immunohistochemical  profile  of  the  precancerous  lesions  and  pancreatic  ductal 
adenocarcinoma of p16flox/flox; LSL-KrasG12D; Pdx1-Cre mice.
Marker Normal PanIN-1* PanIN-2 PanIN-3 PDA*
Fascin - +/- ++ ++ +++
Ki67 +/- +/- + ++ ++
Her-2 - - + ++ ++
Cyclin D1 - +/- + ++ +++
Cox-2 - - + ++ ++
* PanIN, pancreatic intraepithelial neoplasia; PDA, pancreatic ductal adenocarcinomaOncotarget 2011; 2:  862 - 873 868 www.impactjournals.com/oncotarget
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Figure 5: Loss of the wild-type allele of Kras is associated with invasiveness and metastasis of pancreatic tumors in 
p16flox/flox; LSL-KrasG12D; Pdx1-Cre mice. (A) Representative samples showing loss of the wild-type allele of Kras (LOH at Kras) 
occurred more frequently in cancer cell lines derived from metastases than those derived from primary tumors of p16flox/flox; LSL-KrasG12D; 
Pdx1-Cre mice by PCR of genomic DNA, and confirmed by. (B) LOH at Kras was confirmed by RT-PCR and restriction fragment length 
polymorphism analyses [18]. PCR-amplified cDNA was untreated (-) or digested with HindIII (+). Representative pancreatic cancer cell 
lines 1 to 3 contained both wild-type (upper band) and mutant Kras alleles (lower band), whereas cell lines 4 and 5 lacked the wild-type 
Kras allele. (C, D) In colony formation assay with soft agar, primary pancreatic cancer cell lines with LOH at Kras formed significantly 
more colonies (23.7± 1.5) than those retained the Kras allele (10.0±2.0) (p<0.05). There was no significant difference between metastatic 
cells with or without LOH at Kras (51.0±14.9 vs. 41.3±6.1; P>0.05). (E) LOH at Kras also promoted cellular proliferation of the primary 
cancer cell lines in low serum environment at day 1(P<0.01) and day 2 (p<0.05) by MTT assay. (F, G) Increased migration was also 
correlated with LOH at Kras as measured by percentage of wound healing at 24 hours. The data represent the mean ± SD (n=3, p< 0.05).Oncotarget 2011; 2:  862 - 873 869 www.impactjournals.com/oncotarget
and histology. 
Loss  of  the  wild-type  Kras  allele  promotes 
pancreatic tumor cell proliferation and metastasis 
in mice and humans
Primary cell cultures were established from 12 
primary tumors and 2 metastases of the p16flox/flox; 
LSL- KrasG12D; Pdx1-Cre mice (Two of the 12 primary 
tumors and the two metastases were harvested from 
the same mice). From these primary cell cultures, we 
further established 464 clonal cancer cell lines from the 
12 pancreatic primary tumors and 42 clonal cancer cell 
lines from the metastasis. Smad4 and p19 proteins were 
detected in all the clonal cancer cell lines examined (Fig. 
S5). We sequenced p53 cDNA of ~100 clonal cancer cell 
lines but did not uncover any p53 mutation in these cells. 
 LSL-KrasG12D was conditionally activated in all of 
the pancreatic cancer cell lines (Fig. 5A), indicating that 
Kras activation is required for pancreatic tumorigenesis in 
these mice. Surprisingly, some of the cell lines possessed 
only the recombined Kras allele, but not the wild-type 
Kras allele (Fig. 5A). RT-PCR/RFLP analysis of RNA 
confirmed that the wild-type allele of Kras was lost (LOH 
at Kras) in some tumor cell lines but never the mutant 
KrasG12D allele (Fig. 5B). Comparing the cell lines derived 
from the two paired primary tumors and metastases 
derived from the same mice, the frequency of LOH at Kras 
was greater among the cancer cell lines derived from each 
metastasis (8.3% and 33.3%) than those derived from the 
corresponding primary pancreatic tumor (0% and 17.6%, 
respectively) (p=0.16 and p<0.05, respectively) (Fig. 5A), 
suggesting Kras LOH might promote metastasis in vivo. 
We also microdissected liver metastases to confirm that 
LOH at Kras indeed occurred in vivo, and was not an 
artifact generated by tissue culture adaptation (Fig. S6).
To investigate if LOH at Kras has any phenotypic 
consequences, cancer cell lines derived from the primary 
tumor and metastasis of the same p16flox/flox; LSL- KrasG12D; 
Pdx1-Cre mouse were subjected to in vitro assays. In 
soft-agar colony formation assays, clonal cell lines of 
the primary tumor with LOH at Kras (23.7±1.5) formed 
more colonies than those without LOH at Kras (10.0±2.0) 
(p<0.05). The numbers of colonies formed by cell lines 
from the metastasis were generally greater than those 
of the primary tumor cells, but the difference between 
the metastatic cell lines with or without LOH at Kras 
(51.0±14.9 vs. 41.3±6.1 respectively) was not statistically 
significant  (Fig.  5C,  D).  Under  low  serum  condition, 
significant increased proliferation was observed in primary 
tumor cell lines with LOH at Kras than those without 
(Fig. 5E). Loss of the wild-type Kras allele also promoted 
motility among the primary cancer cell lines significantly 
(Fig 5F, G). Real-time PCR did not detect amplification 
of the mutant Kras allele in primary or metastatic cancer 
cell lines and confirmed the loss of the wild-type Kras 
allele (Table S3); indicating that the functional differences 
observed in these cancer cell lines were not caused by 
Figure 6: Increased LOH at KRAS (chromosome 12p) in human metastases compared with primary pancreatic 
cancers. SNP analyses were performed on human cancer cell lines derived from pancreatic primary tumors (n=19) or metastases (n=10). 
High frequency allelic loss was exclusively observed at chromosome 12p (where KRAS is located) in metastatic cells, but not primary tumor 
cells (p<0.02).
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differential mutant Kras amplification, but rather by the 
loss of the wild-type Kras allele. We investigated whether 
the MAPK signaling pathway is responsible for the 
functional differences observed in primary and metastatic 
cancer cell lines with or without LOH at Kras and found 
no discernible difference of ERK1/2 phosphorylation in 
cancer cell lines with or without LOH of Kras by western 
blot analyses. 
Our in vivo and in vitro data suggested that LOH 
at  Kras rendered primary pancreatic tumor cells more 
aggressive functional phenotypes that favored growth and 
metastasis in mice. To investigate if such phenomena also 
occurs in humans, non-biased whole-genome LOH profiles 
were generated from human cancer cell lines derived from 
primary pancreatic tumors (n=19) or metastases (n=10). 
There was no statistical difference in the LOH profiles of 
the primary tumors vs. metastases except at chromosome 
12p, which contains the KRAS gene. LOH at chromosome 
12p was observed in 37% of primary and 80% of metastatic 
cancer cell lines (p<0.02) (Fig. 6). LOH at KRAS was 
confirmed by genomic sequencing of the KRAS gene in 
the cancer cell lines with LOH at chromosome 12p (Fig. 
S7). The lack of significant difference in the allelic loss on 
other chromosomes strongly supports that the increased 
LOH at chromosome 12p is a selective and targeted event. 
These data corroborates the observations made in our 
mice, suggesting that LOH at KRAS is associated with 
metastasis and may promote metastasis.
DIscUssION 
We reported the first mouse line with conditional 
knockout of p16 that does not alter p19 expression (Fig. 
1, S6). This mouse strain is distinct from the previously 
reported p16/p19 knockout strains [18, 21]. These mice 
are useful for investigating the functions of p16, without 
disrupting the p19-Mdm2-p53 pathway, in tissue-specific 
manners. 
In combination with expression of KrasG12D, pancreas-
specific disruption of p16 in LSL- KrasG12D; Pdx1-Cre mice 
promoted progression of mPanIN to invasive pancreatic 
ductal  adenocarcinoma  and  significantly  shorten  their 
median survival from >13 months to 4-6 months (Fig. 2) 
[25]. The p16-/-; LSL- KrasG12D; Pdx1-Cre mice and p16flox/
flox; LSL- KrasG12D; Pdx1-Cre mice had median survival 
times of 4 and 6 months respectively—longer than the 
2-month average survival time reported for p16/p19flox/flox; 
LSL- KrasG12D; Pdx1-Cre and p16/p19-/-; LSL- KrasG12D; 
Pdx1-Cre mice [18, 21]. The survival curves of p16/
p19flox/flox; LSL- KrasG12D; Pdx1-Cre and p16/p19-/-; LSL- 
KrasG12D; Pdx1-Cre mice  more closely resemble those 
of p53flox/flox; LSL- KrasG12D; Pdx1-Cre mice, perhaps due 
to the fact that p19 and p53 belong in the same pathway. 
Therefore it is important to differentiate the contributions 
of p16 and p19 to pancreatic tumorigenesis.
Similar mPanIN progression profile was observed 
in  p16-/-; LSL- KrasG12D; Pdx1-Cre and p16flox/flox; LSL- 
KrasG12D; Pdx1-Cre mice as in LSL-KrasG12D; PDX1-Cre 
mice but at an accelerated pace (Fig. 4), indicating that 
biallelic inactivation of p16 accelerated the development 
of PDA in synergy with KrasG12D but did not alter the 
pathological progression of the pancreatic lesions- 20% 
of the pancreatic ducts in p16-/-; LSL- KrasG12D; Pdx1-
Cre mice had mPanIN presentations around 4 weeks of 
age (Fig. 4), as opposed to >2 months in LSL-KrasG12D; 
PDX1-Cre mice [11]. The mPanIN lesions evolved and 
progressed to invasive cancer, and the most common 
histologic variant was comprised predominantly of 
malignant glands characterizing a well to moderately 
differentiated adenocarcinoma (Fig. 2, S3, Tables S1, S2). 
This is in contrast to the undifferentiated sarcomatoid 
histology previously reported in p16-/-; LSL- KrasG12D; 
Pdx1-Cre mice (n=3) [21]. The difference may simply 
be in the number of mice examined, but nevertheless, 
given that the majority of human pancreatic cancer is 
presented as well to moderately differentiated ductal 
adenocarcinoma, it’s important that we have demonstrated 
here that biallelic inactivation of p16 in conjunction with 
oncogenic Kras in mice mimic human pancreatic tumor 
progression from PanIN to PDA. 
A striking feature of the p16-/-; LSL- KrasG12D; Pdx1-
Cre and p16flox/flox; LSL- KrasG12D; Pdx1-Cre mice was the 
high penetrance of metastases. Metastases were observed 
in 100% of the non-thriving p16-/-; LSL- KrasG12D; Pdx1-
Cre mice (n=14). It has been reported previously that 
only 63% of p53R172H/+; LSL-KrasSG12D; PDX1-Cre mice 
developed metastasis [25, 26], 33% was detected in 
p53lox/+; LSL-KrasG12D; PDX1-Cre mice,  and none was 
reported in p53lox/lox; LSL-KrasG12D; PDX1-Cre mice [21, 
26]. It appears that inactivation of p16 in the presence of 
activated Kras is associated with increased metastasis in 
comparison to p53 inactivation; however, the mechanism 
behind this difference is not known presently. This 
difference in metastasis frequency cannot be explained by 
mere difference in medium survival- the reported medium 
survival of p53R172H/+; LSL-KrasSG12D; PDX1-Cre mice (5 
months) [25] is longer than that of p16-/-; LSL- KrasG12D; 
Pdx1-Cre mice. The frequent and consistent metastases 
observed in the p16-/-; LSL- KrasG12D; Pdx1-Cre and p16flox/
flox; LSL- KrasG12D; Pdx1-Cre mice make them ideal models 
for studying advanced human PDA and metastasis.
Numerous studies in mouse models have shown that 
KrasG12D is sufficient to initiate development of PanINs 
and their progression to invasive cancer [6, 10, 11]. 
Here we show that that in addition to its role in tumor 
initiation, KrasG12D may promote tumor progression and 
metastasis. The loss of the wild-type allele of Kras during 
the progression from primary carcinomas to metastases 
suggests that its loss might confer growth advantage in the 
presence of oncogenic e KrasG12D allele. LOH at Kras did 
not appear to be a random event, because only the wild-
type Kras allele was selectively lost, which resulted in Oncotarget 2011; 2:  862 - 873 871 www.impactjournals.com/oncotarget
discernible functional phenotypes (Fig. 5). LOH at Kras 
was detectable in liver metastases and not a mere result of 
tissue culture adaptation (Fig. S6). LOH at Kras was not an 
artifact created by genetic engineering or unique to mice, 
because an increased frequency of LOH at KRAS was 
observed in human metastatic cell lines (80%) compared 
with primary cancer cell lines (37%) (Fig. 6). KRAS is 
located on chromosome 12p—the only chromosomal 
region in which a statistically significant difference was 
observed between human primary and metastatic cancer 
cells. The absence of increased LOH at other chromosomal 
arm strongly supports that the LOH at KRAS is not simply 
a manifestation of increased genomic stability during 
progression. Previous studies proposed that a wild-type 
allele of Kras allele can serve as a tumor-suppressor [7, 
12, 27-30]. Our data demonstrate that sporadic loss of the 
wild-type Kras allele occurred in pancreatic tumors and 
metastases in both mice and humans. Our data is the first 
to provide in vivo and in vitro evidence that LOH at wild-
type Kras is associated with pancreatic tumor metastasis. 
The functional impacts of oncogenic Kras in tumor 
initiation are well known, but the potential role of wild-
type Kras in this process remains elusive. It is possible 
that the loss of wild-type Kras merely serves to remove a 
competitor for limited resources, such as GTP. However, 
many previous studies have suggested that the dynamics 
between the wild-type and mutant Kras proteins is complex 
and the expression level of the mutant Kras allele and/
or the ratio of the wild-type to mutant Kras proteins are 
critical to tumorigenesis [6-10, 12, 13]. Identification of 
differential downstream effector proteins for wild-type and 
oncogenic KRAS in the future will help elucidating if the 
wild-type KRAS allele possesses any tumor-suppressive 
function. However, regardless what the underlying 
molecular mechanism is, our current study already has 
a strong implication on the development KRAS target 
therapy. The current thinking on KRAS target therapy 
does not differentiate between inhibiting wild-type or 
oncogenic KRAS. Our data strongly recommends that 
future KRAS target therapies should specifically inhibit 
only the oncogenic KRAS, not the wild-type KRAS, 
because the non-discriminatory inhibition of wild-type 
KRAS may promote metastasis and produce unintended 
negative impacts on patient care. 
  We  show  that  biallelic  inactivation  of  the  p16 
and  KrasG12D act synergistically to promote pancreatic 
tumorigenesis and metastasis. The p16flox/flox; LSL- 
KrasG12D; Pdx1-Cre mice develop PanIN, invasive 
tumors, and metastases in a manner that recapitulates 
human PDA development and progression. The relative 
short median survival and high incidence of metastasis 
in these mice make them an attractive model for testing 
novel therapeutics and investigating metastasis—2 areas 
of research that are a challenge to explore in humans. 
MATERIALS AND METHODS
Genetically engineered mouse models and mouse 
strains
To generate a conditional p16 knockout mouse line 
(p16flox/flox),  exon1α  of  p16  was  flanked  by  loxP  sites, 
leaving p19 expression intact (Fig. S1 and 1). The details 
on the generation of the p16flox/flox mouse line are described 
in the Supplementary Methods. The resultant p16flox/flox 
mice were of mixed 129/SvJ and C57BL/6 backgrounds. 
The p16-/- [22] and LSL- KrasG12D [11] mice were obtained 
through the Mouse Models of Human Cancers Consortium 
Repository.  Pdx1-Cre mice were previously described 
[11]. All studies were conducted in compliance with the 
IACUC guidelines of Columbia University. 
Histology and immunohistochemistry
Tissues  were  fixed  in  10%  formalin  overnight 
and  embedded  in  paraffin.  The  detailed  protocol  and 
antibodies for immunohistochemistry are described in the 
Supplementary Methods.
Establishment  and  cultivation  of  primary 
pancreatic adenocarcinoma cell lines
Freshly isolated murine tumor specimens were 
minced with sterile razor blades, digested with 0.5% 
trypsin for 15 minutes at 37°C, resuspended in DMEM 
and 15% fetal bovine serum (FBS), and seeded in 10 
cm dishes. All genetic analyses were performed on cells 
cultivated for less than 7 passages. Each primary cancer 
cell culture was then sorted by flow cytometry and seeded 
at a single cell per well, into 96-well tissue-culture plates, 
to establish clonal cell lines. About 18 to 50 clonal cell 
lines were obtained from each original primary cancer cell 
line.
Immunoblot analysis
Tissues or cell pellets were lysed in 20 mM Tris (pH 
7.5), 150 mM NaCl, 1mM EDTA, 1mM EGTA, and 1% 
Triton X-100 in the presence of a protease inhibitor cocktail 
(Roche, Indianapolis, IN) or and a phosphatase inhibitor 
cocktail (kits I and II, Calbiochem). Immunoblotting was 
performed as described previously [31, 32] and as in the 
Supplementary Methods. 
Colony formation, MTT, and migration assays
These assays were performed with standard protocols 
and briefly described in the Supplementary Methods. All 
experiments were performed in triplicate and repeated at Oncotarget 2011; 2:  862 - 873 872 www.impactjournals.com/oncotarget
least 3 times. 
SNP analyses of human cancer cell lines
Twenty-nine human cancer cell lines were used, and 
segregated into those arising from primary carcinomas 
(BxPc3, MiaPaCa-2, Panc-1, PK9, PL-1, PL-5, PL-9, 
PL-11, PL-13, PL-19, PL20, PL21, PL22, PL23, PL24, 
XPA1, XPA2, XPA3, and A13A/B) or from pancreatic 
cancer metastases (AsPc1, CAPAN1, CFPAC1, Hs766T, 
PK-8, Su86.86, A6L, A2.1, A13D, and A10.7) [33, 34]. 
The allelotypes of 24 of these cell lines were described 
previously  [33],  whereas  those  of  cell  lines  A13A/B, 
A6L, A2.1, A13D and A10.7 were generated for this 
study. The genotypes of 115,353 SNPs were analyzed 
in all cell lines using Affymetrix oligonucleotide arrays 
hybridized to reduced complexity genomic DNA as 
previously described [35]. Genotypes were determined by 
the GeneChip® DNA Analysis Software Tool (GDAST, 
v3.0) using a 0.05 quality score setting genotypes were 
plotted with respect to their genomic position listed in 
the May 2004 assembly of the human genome and briefly 
described in the Supplementary Method. 
Statistical analysis
Results were presented as the mean ± SD. the Student 
t test was used to compare data between groups and the χ2 
method was used to compare the frequency of allelic loss 
among cell lines. P values less than 0.05 were considered 
to be statistically significant.
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